“Axitinib Affects Cell Viability and Migration of a Primary Foetal Lung Adenocarcinoma Culture”

REFERENCES

• El Ouazzani H, Jniene A, Bouchikh M, Achachi L, El Ftouh M, Achir A, El Fassy Fihry MT. Well-differentiated fetal adenocarcinoma: a very uncommon malignant lung tumor. Rev Port Pneumol 2012;18:39–41.
   Google Scholar
• Aleong JC, Calaminici M, Sheaff M. The cytology of pulmonary well-differentiated foetal adenocarcinoma. Cytopathology 2006;17:155–156.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244–285.
   PubMed Web of Science ®Google Scholar
• Nakatani Y, Miyagi Y, Takemura T, Oka T, Yokoi T, Takagi M, Yokoyama S, Kashima K, Hara K, Yamada T, Nozawa A, Inayama Y, Sakamoto K, Ogawa N, Kitamura H, Resl M, Cho SH, Koss MN, Mark EJ. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 2004;28:921–927.
   Google Scholar
• Nakatani Y, Kitamura H, Inayama Y, Kamijo S, Nagashima Y, Shimoyama K, Nakamura N, Sano J, Ogawa N, Shibagaki T, Resl M, Mark EJ. Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am J Surg Pathol 1998;22:399–411.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xu ML, Zhong HH, Heng WJ, Wu BQ. EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinoma. Pathol Oncol Res 2008;14:373–379.
   PubMed Web of Science ®Google Scholar
• Garib T, Chen G, Huang C Misek DE, Iannettoni MD, Hanash SM, Orringer MB, Beer DG. Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas. Clin Lung Cancer 2004;5:307–312.
   PubMedGoogle Scholar
• Shijubo N, Su Uede T, Kon S, Maeda M, Segawa T, Imada A, Hirasawa M, Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 1999;160:1269–1273.
   PubMed Web of Science ®Google Scholar
• Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol/Hematol 2007;62:179–213.
   PubMed Web of Science ®Google Scholar
• Kradin RL, Young RH, Dickersin GR, Dickersin GR, Kirkham SE, Mark EJ. Pulmonary blastoma with argyrophil cells and lacking sarcomatous features (pulmonary endodermal tumor resembling fetal lung). Am J Surg Pathol 1982;6:165–172.
   Google Scholar
• Kodama T, Shimosato Y, Watanabe S, Koide T, Naruke T, Shimase J. Six cases of well-differentiated adenocarcinoma simulating fetal lung tubules in pseudoglandular stage. Comparison with pulmonary blastoma. Am J Surg Pathol 1984;8:735–744.
   PubMed Web of Science ®Google Scholar
• Amirat L, le Pimpec Barthes F, Danel C, Poulet B, Riquet M. Well differentiated fetal-type pulmonary adenocarcinoma: a tumour with a good prognosis. Rev Mal Respir 2003;20:429–432.
   PubMed Web of Science ®Google Scholar
• Fujino S, Asada Y, Konishi T, Asakura S, Kato H, Mori A. Well-differentiated fetal adenocarcinoma of lung. Lung Cancer 1995;13:311–316.
   Google Scholar
• Ma PC. Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 2012;79(1), eS56–eS60.
   PubMedGoogle Scholar
• Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244–285.
   PubMed Web of Science ®Google Scholar
• Labitzke R, Friedl P. A serum-free medium formulation supporting growth of human umbilical cord vein endothelial cells in long-term cultivation. Cytotechnology 2001;35:87–92.
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nature Protocols 2006;1:2315–2319.
   PubMed Web of Science ®Google Scholar
• Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman J. Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res 2008;14:6867–6876.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 2012;75:161–166.
   PubMed Web of Science ®Google Scholar
• Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006;6:277. doi:10.1186/1471-2407-6-277.
   PubMed Web of Science ®Google Scholar
• Cao YD, Huang PL, Sun XC, Ma J, Jin ZL, Cheng HY, Xu RZ, Li F, Qin SK, Deng YX, Ge XL. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells. Chin Med J (Engl) 2011;124:1061–1068.
   PubMed Web of Science ®Google Scholar
• Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009;15:3495–3502.
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272–7283.
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790–799.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non–small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857–865.
   PubMed Web of Science ®Google Scholar
• De Falco E, Scafetta G, Napoletano C, Puca R, Vingolo EM, Ragona G, Iorio O, Frati G. A standardized laboratory and surgical method for in vitro culture isolation and expansion of human primary human Tenon's fibroblasts. Cell Tissue Bank 2013;14:277–287.
   PubMed Web of Science ®Google Scholar
• Scafetta G, Tricoli E, Siciliano C, Napoletano C, Puca R, Vingolo EM, Cavallaro G, Polistena A, Frati G, De Falco E. Suitability of human Tenon's fibroblasts as feeder cells for culturing human limbal epithelial stem cells. Stem Cell Rev Rep 2013. doi 10.1007/s12015-013-9451-6.
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790–799.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857–865.
   PubMed Web of Science ®Google Scholar
• Pacinda SJ, Ledet SC, Gondo MM, Langston C, Brown RW, Carmona PA, Franklin RB, Roggli VL, Cagle PT. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. Hum Pathol 1996;27:542–546.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–364.
   PubMed Web of Science ®Google Scholar
• Fukumura, D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;74:72–84.
   PubMed Web of Science ®Google Scholar
• De Donatis A, Ranaldi F, Cirri P. Reciprocal control of cell proliferation and migration. Cell Commun Signal 2010;8:20. doi: 10.1186/1478-811X-8-20.
   PubMedGoogle Scholar
• Martens UM. Small Molecules in Oncology. Recent Results in Cancer Research, Volume 184, PM Schlag and HJ Senn (eds.). Berlin: Springer, 2010, 33–42.
   Google Scholar